Experimental Study of LY333328 (Oritavancin), Alone and in Combination, in Therapy of Cephalosporin-Resistant Pneumococcal Meningitis

Using a rabbit model of meningitis, we sought to determine the efficacy of LY333328, a semisynthetic glycopeptide, in the treatment of cephalosporin-resistant pneumococcal meningitis. LY333328 was administered at a dose of 10 mg/kg of body weight/day, alone and in combination with ceftriaxone at 100...

Ful tanımlama

Kaydedildi:

Detaylı Bibliyografya
Yayımlandı:	Antimicrob Agents Chemother
Asıl Yazarlar:	Cabellos, Carmen, Fernàndez, Antonio, Maiques, Jose M., Tubau, Fe, Ardanuy, Carmen, Viladrich, Pedro F., Liñares, Josefina, Gudiol, Francesc
Materyal Türü:	Artigo
Dil:	Inglês
Baskı/Yayın Bilgisi:	American Society for Microbiology (ASM) 2003
Konular:	Experimental Therapeutics
Online Erişim:	https://ncbi.nlm.nih.govhttps://pmc.ncbi.nlm.nih.gov/articles/PMC155831/ https://ncbi.nlm.nih.govhttps://pubmed.ncbi.nlm.nih.gov/12760866/ https://ncbi.nlm.nih.govhttps://doi.org/10.1128/AAC.47.6.1907-1911.2003
Etiketler:	Etiketle Etiket eklenmemiş, İlk siz ekleyin!

Experimental Study of LY333328 (Oritavancin), Alone and in Combination, in Therapy of Cephalosporin-Resistant Pneumococcal Meningitis

Benzer Materyaller